--- title: "Sigrid Therapeutics appoints Claus Kjærsgaard as Chief Executive Officer" type: "Company News" date: "2026-01-28" updated: "2026-10-07" description: "Sigrid Therapeutics (Sigrid), a science-driven consumer health company developing innovative solutions for metabolic health, today announced the appointment of Claus Kjaersgaard as its new Chief…" url: "https://sipore.com/insights/claus-kjaersgaard-appointed-ceo" canonical: "https://sipore.com/insights/claus-kjaersgaard-appointed-ceo" markdown_url: "https://sipore.com/insights/claus-kjaersgaard-appointed-ceo.md" site: "SiPore" publisher: "SiPore Technologies (Sigrid Therapeutics AB)" contact: "contact@sipore.com" language: "en" --- # Sigrid Therapeutics appoints Claus Kjærsgaard as Chief Executive Officer *Company News · Jan 28, 2026* > Sigrid Therapeutics (Sigrid), a science-driven consumer health company developing innovative solutions for metabolic health, today announced the appointment of Claus Kjaersgaard as its new Chief… Sigrid Therapeutics (Sigrid), a science-driven consumer health company developing innovative solutions for metabolic health, today announced the appointment of Claus Kjaersgaard as its new Chief Executive Officer. Claus will assume the role on 1 February 2026. Claus brings more than 15 years of experience across marketing, sales, and business development within FMCG, pharmaceuticals, and healthcare. ## Deep experience across regulated health Most recently, he served as CEO of Otivio AS, where he led the company’s global commercial strategy for medical devices. He previously served as CEO of Smartfish AS and has held senior roles at Pronova BioPharma and GlaxoSmithKline. “I am thrilled to join Sigrid at a pivotal moment for the metabolic health category, said Claus Kjaersgaard. “With its patented SiPore® technology, Sigrid is uniquely positioned to help reshape and revitalise this space in a more sustainable, science-led way.” Mattias Ankarberg, Chairman of the Board of Sigrid, commented: “I am very pleased to welcome Claus Kjaersgaard as our new CEO. Claus has a strong track record of building and scaling health-focused businesses, combining strategic clarity with deep customer and market insight. His experience across regulated health products, international commercialisation, and partnership-driven growth makes him exceptionally well suited to lead Sigrid into its next phase. I would also like to thank Sana Alajmovic for building the strong scientific and commercial foundation of Sigrid and wish her the very best in her next role.” ## About SIGRID SIGRID is a Swedish consumer health company developing technologies designed to reduce the metabolic impact of modern meals. The company’s patented SiPore® technology works locally in the gastrointestinal tract by interacting with digestive enzymes involved in carbohydrate and fat digestion. By slowing nutrient breakdown during digestion, SiPore® supports steadier post-meal metabolic responses. SIGRID collaborates with clinicians, researchers, and health innovators to translate metabolic science into practical solutions supporting metabolic health, weight management, and glucose stability. The company was founded in 2014 and is headquartered in Stockholm, Sweden. Originally published by Sigrid Therapeutics on Jan 28, 2026. [Read the original announcement →](https://www.mynewsdesk.com/sigrid/pressreleases/sigrid-therapeutics-appoints-claus-kjaersgaard-as-chief-executive-officer-3437273) ## Related articles - [SiPore® Practitioner Portfolio Now Available on Fullscript, Expanding Access to Gut-Local Metabolic Health Solutions Across the United States](https://sipore.com/insights/sipore-practitioner-portfolio-on-fullscript.md) — Company News, 2026-08-05 - [Sigrid Therapeutics Launches on Fullscript, Expanding U.S. Practitioner Access](https://sipore.com/insights/sigrid-launches-on-fullscript.md) — Company News, 2026-08-05 ## How to cite SiPore Technologies (Sigrid Therapeutics AB). “Sigrid Therapeutics appoints Claus Kjærsgaard as Chief Executive Officer”. SiPore, 2026-01-28. https://sipore.com/insights/claus-kjaersgaard-appointed-ceo (accessed ). Use the trademarks as written: SiPore®, Carb Fence™. For the SHINE trial, cite the peer-reviewed publication in *eClinicalMedicine* (The Lancet Discovery Science, 2026) rather than this page. ## Company & contact - **Company:** SiPore Technologies — legal entity Sigrid Therapeutics AB (Swedish org.nr [556958-3023](https://www.allabolag.se/foretag/sigrid-therapeutics-ab/sundbyberg/forskning/2K3ZHRJI5YE3M)) - **Stockholm headquarters:** Vasagatan 14A, 172 61 Sundbyberg, Sweden ([map](https://www.google.com/maps/search/?api=1&query=Vasagatan%2014A%2C%20172%2061%20Sundbyberg%2C%20Sweden)) - **General enquiries:** [contact@sipore.com](mailto:contact@sipore.com) - **Partnerships & licensing:** [partnerships@sipore.com](mailto:partnerships@sipore.com) - **Origin:** Founded in Stockholm, Sweden - **Taglines:** “The meal companion for modern food.” · “Same meal. Less impact.” · “Scandinavian science. Global impact.” · “Precision science for the modern meal.” - **About:** SiPore® is a patented meal-companion technology designed to reduce the impact of modern meals at the level of digestion. **Our sites** — all sites owned and operated by Sigrid Therapeutics AB: - [SiPore.com](https://www.sipore.com/): Technology, science & partnerships - [SiPorePro.com](https://www.siporepro.com/): Practitioner products & professional resources - [SigridLife.com](https://sigridlife.com/): SIGRID consumer products - [SigridStabiliser.se](https://sigridstabiliser.se/): SIGRID Sweden --- [View on site](https://sipore.com/insights/claus-kjaersgaard-appointed-ceo) · [All insights](https://sipore.com/insights.md) · [Site index for agents (llms.txt)](https://sipore.com/llms.txt)